NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis.

Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancersNXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter

Nuvectis Pharma (NASDAQ:NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in non-small cell lung cancer (NSCLC) cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib and lorlatinib, showcasing NXP900's potential to address resistance mechanisms in NSCLC. Also, with the growing anticipation of the data update from NXP800 expected soon from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, Nuvectis is positioning itself at the forefron

Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC on Molecular Targets and Cancer Therapeutics (October 23-25, 2024, Barcelona, Spain). Titles and Presenters Presentation Details Title NXP900, a novel YES1/SRC kinase inhibitor in phase 1 dose escalation, demonstrates potent synergy with ALK inhibitors in ALK resistant cell lines Presenter Asier Unciti-Broce

Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Event Annual ROTH Healthcare Opportunities Conference Panel Title Innovative Therapies for Solid Tumors Date and Time October 9, 2024, 12:30 pm ET About Nuvectis Phar

With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma's NXP900 could hold similar transformative potential in NSCLC as Summit Therapeutics's Ivonescimab The Bottom Line Summit Therapeutics (NASDAQ:SMMT) recently reported Ivonescimab's Phase 3 results from study conducted in China that showed significant efficacy in addressing NSCLC treatment resistance, surpassing Merck's Keytruda in key outcomes and sending SMMT stock skyrocketing. Like Ivonescimab, Nuvectis Pharma's (NASDAQ:NVCT) NXP900 tackles resistance in NSCLC but targets a different pathway by inhibiti

Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference. EventH.C. Wainwright Global Investment ConferenceDateSeptember 9, 2024Time12:00 PM ETLinkhttps://journey.ct.events/view/5bacb2fb-d0c8-4efa-92b8-7365c030ddd5 About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development

FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration ("FDA") for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We are very pleased to have received this designati

FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the second quarter 2024 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "During the second quarter we continued to advance our clinical trials for NXP800 and NXP900. For NXP800, the Phase 1b clinical trial in platinum resistant, ARID1a-mutated ovarian cancer is continuing to enroll

Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City. Event H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Date May 20th, 2024 Time 12:00 PM Eastern Time Link Fireside Chat [Link] About Nuvectis Pharma, Inc. Nuvectis Pharma

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

HC Wainwright & Co. initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $14.00

10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

DEFA14A - Nuvectis Pharma, Inc. (0001875558) (Filer)

DEF 14A - Nuvectis Pharma, Inc. (0001875558) (Filer)

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.40) by 37.5 percent. This is a 7.41 percent increase over losses of $(0.27) per share from the same period last year.

Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTMSingle Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in AlecensaTMFort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved fo

Gainers Aptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 23.65% to $11.92. The company's market cap stands at $211.8 million. Bright Green (NASDAQ:BGXX) stock moved upwards by 20.99% to $0.34. The market value of their outstanding shares is at $62.5 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 14.38% to $1.59. The market value of their outstanding shares is at $55.2 million. Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 13.57% to $8.2. The company's market cap stands at $251.0 million. Annexon (NASDAQ:ANNX) stock mov

 33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also ObservedPlatinum-Resistant Ovarian Cancer is a Devastating Serious Condition of Unmet Medical Need with a Median Life Expectancy of Approximately One Year 

NUVECTIS PHARMA, INC.STATEMENT OF OPERATIONS(USD in thousands, except per share and share amounts)For the year endedFor the year endedDecember 31, 2023December 31, 2022OPERATING EXPENSES:Research and development15,38013,227General and administrative7,5176,007OPERATING LOSS(22,897)(19,234)Finance income637149NET LOSS(22,260)(19,085)NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS(22,260)(19,085)BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING(1.43)(1.51)Basic and diluted weighted average number of common shares outstanding15,556,65512,657,651 

Gainers Celularity (NASDAQ:CELU) shares moved upwards by 44.7% to $0.27 during Thursday's regular session. The company's market cap stands at $52.8 million. NovoCure (NASDAQ:NVCR) shares increased by 24.15% to $15.42. The market value of their outstanding shares is at $1.6 billion. Jasper Therapeutics (NASDAQ:JSPR) shares moved upwards by 22.18% to $13.0. The market value of their outstanding shares is at $145.0 million. Nuvectis Pharma (NASDAQ:NVCT) shares moved upwards by 14.85% to $8.46. The company's market cap stands at $146.6 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock rose 14.74% to $3.66. The market value of their outstanding shares is at $22.3 million. Venus Concept (NASDAQ

Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by investigators from Mayo Clinic in PDX models of cholangiocarcinoma (presented at the 2023 American Association for Cancer Research ("AACR"))NXP800 was granted orphan drug designation by the FDA for the treatment of cholangiocarcinoma in August 2023Fort Lee, NJ, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.34) by 8.82 percent. This is a 11.9 percent increase over losses of $(0.42) per share from the same period last year.